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Introduction
An increasing incidence of thyroid cancer has been reported 
in most populations worldwide [1, 2]. Thyroid cancer is 
the fifth most common cancer in women in the United 
States, accounting for approximately 5% of all cancer [3]. 
Recently, a rise in thyroid cancer incidence rate has also 
been reported in pediatric patients, mainly among ado-
lescents [3, 4]. In fact, thyroid cancer is the second most 
prevalent cancer in females with 15–19 years of age [5]. 
Similar to adults, the great majority of pediatric follicular 
cell- derived thyroid carcinomas are papillary thyroid car-
cinomas (PTC), with nearly 75–90% of cases [6].
The clinical presentation and outcomes of thyroid car-
cinoma differ between pediatric and adult population. 
Although pediatric patients are more likely to present a 
more advanced stage of disease at diagnosis and higher 
risk of recurrent and persistent disease than adults, they 
usually have an excellent overall survival [7, 8]. Furthermore, 
a great heterogeneity within the pediatric group has been 
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Abstract
Thyroid cancer is the fastest increasing cancer worldwide in all age groups. 
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer 
in both adults and children. PTC genomic landscape has been extensively studied 
in adults, but information regarding sporadic pediatric patients is lacking. 
Although BRAF V600E mutation is highly prevalent in adults, this mutation is 
uncommon in pediatric cases. As adult and pediatric PTC is a mitogen- activated 
protein kinase- driven cancer, this altered pathway might be activated by differ-
ent genetic events. The aim of this study was to investigate the occurrence of 
AGK-BRAF fusion gene, recently described in radiation- exposed pediatric PTC, 
in a cohort of exclusively sporadic pediatric PTC. The series consisted of 30 
pediatric PTC younger than 18 years of age at the time of diagnosis and 15 
matched lymph node metastases (LNM). Primary tumors and matched LNM 
were screened for the presence of the AGK-BRAF fusion transcript by RT- PCR. 
To confirm the identity of the amplified products, randomly selected samples 
positive for the presence of the fusion transcripts were sequenced. Moreover, 
BRAF dual- color, break- apart probes confirmed BRAF rearrangement. Overall, 
the AGK-BRAF fusion gene was detected in 10% (3/30) of primary tumors. 
For one of these cases, paired LNM was also available, which also shows the 
presence of AGK-BRAF fusion gene. This study described, for the first time, 
the presence of AGK-BRAF in sporadic pediatric PTC. Understanding the molecu-
lar events underlying pediatric PTC may improve preoperative diagnosis, allow 
molecular prognostication and define a therapeutic approach toward sporadic 
PTC patients.
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reported. Some studies have suggested worse outcome for 
children compared to adolescents [9, 10].
It is still unclear whether the clinicopathological differ-
ences observed between pediatric and adult population may 
be due to the existence of distinct genetic alterations. In 
fact, the frequency and spectrum of mutations in adult 
PTC is markedly different than that in pediatric PTC [11, 
12]. Some studies have also reported a different spectrum 
of mutations within pediatric group. Actually, the prevalence 
of the BRAF V600E mutation, the most common genetic 
event found in adult PTC [13], is significantly lower in 
sporadic and radiation- exposed pediatric PTC [14, 15, 18]. 
On the other hand, a high prevalence of genetic rearrange-
ments has been described in both sporadic [11, 16] and 
radiation- exposed pediatric thyroid carcinomas [17, 18].
Interestingly, BRAF rearrangements, in which the BRAF 
kinase domain is fused to a variety of 5′ partners, have 
been reported in several solid tumors types [19] as well 
as in PTC [20]. The new fusion gene (AKAP9-BRAF) was 
found in radiation- exposed PTCs and results from an in- 
frame fusion of the exons 1–8 of the AKAP9 gene (A- kinase 
anchor protein 9) to exons 9–18 of BRAF gene [20].
As BRAF fusion represent an alternative mechanism of 
BRAF activation, one could hypothesize that BRAF could 
be activated in pediatric PTCs through rearrangement. In 
fact, recently, AGK-BRAF rearrangement was described in 
one case of radiation- exposed pediatric PTC, but was not 
identified in pediatric cases from patients with unknown 
radiation exposure [18]. This rearrangement was caused 
by an inversion of the long arm of chromosome 7, which 
juxtaposes the exons 1 and 2 of the AGK (acylglycerol 
kinase) to exons 8–18 of BRAF [18]. The expression of 
this fusion oncogene promotes a constitutive activation of 
MEK and ERK phosphorylation, thus activating the mitogen- 
activated protein kinase (MAPK) cascade [18]. AGK-BRAF 
was later described in one PTC from adult patient with 
apparently no history of radiation exposure [21].
To elucidate alternative mechanisms of aberrant BRAF 
activation, this study investigated the presence of AGK-
BRAF fusion oncogene in a cohort of predominantly 
sporadic pediatric PTC.
Material and Methods
Thyroid Samples
The series consists of 45 formalin- fixed paraffin- embedded 
(FFPE) sections from 30 primary PTC and 15 matched 
lymph node metastases (LNM) from patients who under-
went thyroid surgery from 1993 through 2012 at Hospital 
São Paulo (Universidade Federal de São Paulo) and Hospital 
da Santa Casa de São Paulo. All samples were reviewed 
by two pathologists (RD and MTSA). As recommended 
by the ATA guidelines, all pediatric patients included in 
this study were ≤18 years of age at the time of diagnosis 
[22]. The study was conducted under the approval of the 
Review Boards and Research Ethical Committees of the 
affiliated institutions.
RNA isolation and cDNA synthesis
Total RNA was isolated from 10- μm thick FFPE sections 
using the Recover All Total Nucleic Acid isolation kit 
(Ambion Inc., Austin, TX). Total RNA (500 ng) was 
treated with DNAse and reverse- transcribed into cDNA 
with both 50 μM oligo(dT)12-18 and 50 ng random  hexamers 
using a Superscript III transcriptase kit (Invitrogen Corp., 
Carlsbad, CA).
Transient transfection of AGK-BRAF fusion 
gene in thyroid cells
FTC 238 thyroid carcinoma cells, established from a lung 
metastases of a human follicular thyroid carcinoma, pur-
chased from the European Collection of Cell Cultures 
(ECACC, Health Protection Agency, Salisbury, UK) were 
cultured in Dulbecco’s modified essential medium 
(DMEM):Ham’s F12 (1:1) medium supplemented with 
5% fetal bovine serum (FBS) (Life Technologies, Carlsbad, 
CA). FTC 238 cells were transiently transfected with 10 μg 
of pLVX- AGK-BRAF plasmid by electroporation using a 
Gene Pulser II (Bio- Rad Laboratories Inc., Hercules, CA). 
The oncogene- transfected cells were harvested, and the 
total RNA was isolated using TRIzol Reagents (Invitrogen 
Corp.) and reverse- transcribed into cDNA, as above men-
tioned. The cDNA generated from cells expressing the 
fusion transcripts was used as a positive control. The 
pLVX- AGK-BRAF plasmid was kindly donated by Dr. 
James Fagin (Memorial Sloan- Kettering Cancer Center).
Detection of AGK-BRAF fusion transcript
All of the samples were screened for the presence of AGK-
BRAF fusion transcript by RT- PCR, as previously described 
[18]. Briefly, cDNA (2 μL) was subjected to PCR ampli-
fication using 1.0 unit Platinum Taq DNA Polymerase 
(Invitrogen Corp.) and 2 pmol of each primer, as described. 
The samples were incubated at 95°C for 10 min and then 
subjected to 40 cycles of denaturation at 95°C for 30 sec, 
annealing at 60°C for 30 sec, and polymerization at 72°C 
for 30 sec, with a 5- min final extension at 72°C. The 
efficiency of cDNA synthesis was tested using RPS8 as 
internal control, as previously described [23]. A positive 
and negative control was included in each real- time PCR 
run. The PCR products were resolved on a 2% agarose gel 
and visualized on a Bio- Rad Gel Doc EZ system (Bio- Rad). 
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To confirm the identity of the amplified products, positive 
samples were sequenced using the BigDye Terminator 
Cycle Sequencing Kit (PE Applied Biosystems, Foster City, 
CA). The primers used to detect the AGK-BRAF fusion 
transcript, located in exon 2 of AGK and exon 8 of BRAF, 
were previously described and validated [18].
Dual- color break- apart fluorescence in situ 
hybridization (FISH)
A commercially available dual- color, break- apart assay was 
used to test possible breakage of BRAF gene resulting from 
structural rearrangements. The two differentially labeled 
probes, flanking the BRAF gene, were cohybridized in two 
AGK-BRAF- positive PTCs. Targeted tumor areas were circled, 
following review of the corresponding H&E slide by a patholo-
gist (RD), prior to the FISH assay. A 3- μm thick unstained 
tissue sections were deparaffinized, rehydrated, and incubated 
in the pretreatment solution and washed according to manu-
facturer’s protocol (DAKO, Glostrup, Denmark). Slides were 
then incubated with 5 μL solution containing the labeled 
FISH BRAF probes and IQFISH Fast Hybridization buffer 
(SureFISH break- apart probes; Agilent Technologies, Palo 
Alto, CA) denatured at 80°C for 10 min and hybridized 
overnight at 37°C. Posthybridization wash was performed in 
stringent wash buffer at 65°C and two nonstringent washes 
at room temperature. The slides were then mounted with 
10 μL of Mounting Buffer with 4′,6- diamidino- 2- phenylindole 
(DAPI) as a counterstaining. The FISH results were evaluated 
with fluorescent microscope Zeiss (Zeiss, Oberkochen, 
Germany) using ISIS Karyotype Image System (Metasystems, 
Altlussheim, Germany). At least 100 nonoverlapping and 
intact nuclei were evaluated.
Results
Clinical and pathological features
We systematically investigated the prevalence of AGK-BRAF 
mutation in all primary tumors and matched LNM. Age 
ranged from 4 to 18 years old (mean = 11.36 years). 
Twenty- one patients (70%) were females and 9 (30%) 
were males. The study included 12 classical PTC (CPTC), 
12 follicular variant of PTC (FVPTC), four diffuse scle-
rosing variant of PTC (DSVPTC), and two other variants 
of PTC. The clinical and pathological features evaluated 
are summarized in Table 1.
Recurrent AGK-BRAF rearrangement in 
sporadic pediatric PTCs
In order to optimize RT- PCR reaction, we primarily used 
cDNA obtained from FTC cells transiently transfected with 
plasmid containing the AGK-BRAF fusion gene. Different 
primer concentrations and PCR conditions were assayed. 
AGK- BRAF was found in two primary tumors. Moreover, 
in one patient AGK-BRAF rearrangement was identified 
in the LNM, while the fusion gene was not observed in 
the paired primary tumor. As this patient presented a 
multifocal PTC (case 21), additional foci were selected 
for further investigation. One out of five foci presented 
the AGK-BRAF fusion oncogene. Overall, the AGK-BRAF 
fusion gene was found in nearly 10% (3/30) of primary 
tumors and in about 6% (1/15) of LNMs (Table 1; Fig. 1). 
The presence of AGK-BRAF fusion oncogene was con-
firmed by sequencing analysis (Fig. 1).
Additionally, two cases that were positive for AGK-BRAF 
by RT- PCR were selected to test possible breakage of the 
BRAF gene and, therefore, to confirm the BRAF rear-
rangement. In addition to the fused yellow or red- green 
signal, the selected fields showed the presence of red and 
green split signals (Fig. 1). The split- apart BRAF signal 
was identified in 30% and 36% of cells. Nearly 70% of 
cells exhibited only two fused yellow or red- green signals, 
confirming tumor heterogeneity.
AGK-BRAF fusion oncogene and clinical- 
pathological features of sporadic pediatric 
PTC
Among three patients positive for AGK-BRAF, the mean 
age at diagnosis was 11.66 years (range 7–15 years). Two 
tumors with AGK-BRAF fusion were of classical histology 
and one of follicular variant. Extrathyroidal extension 
was observed in all patients with AGK-BRAF rearrange-
ment. The prevalence of patients with distant metastasis 
at diagnosis and multifocality was higher in the AGK- 
BRAF- positive groups than in AGK- BRAF- negative groups 
(Table 2).
Discussion
The Cancer Genome Atlas (TCGA) Research Network, 
using different platforms combined with clinicopathological 
data, characterized the genomic landscape of nearly 500 
PTCs of adults. The study confirmed that PTC is a MAPK- 
driven cancer, identified new cancer- causing gene muta-
tions, as well as new fusion transcripts and somatic copy 
number alteration. These findings reduced the so- called 
“dark matter” of the PTC. Importantly, the large collec-
tion of genetic alterations, combined with a comprehensive 
transcriptomic and proteomic analysis, exposed fundamen-
tal biological variances between PTCs. This increased 
knowledge helped to stratify PTC into subgroups, which 
eventually will improve preoperative diagnosis of thyroid 
nodules, prognosis, and treatment of adult PTC [21].
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Despite intensive efforts, much less is known about the 
genetic alterations that are, in fact, “driver genes” in pedi-
atric PTC. Although pediatric PTCs are also a MAPK- driven 
cancer, the spectrum of mutations differs between adults 
and pediatric tumors. Furthermore, radiation- exposed and 
sporadic pediatric PTCs likely have different genetic land-
scapes. In fact, Nikiforov et al. [17], provided the first 
evidence that they have different molecular signature. The 
authors reported that the prevalence of RET/PTC rearrange-
ments is markedly different between sporadic and radiation- 
exposed pediatric PTC. Not only the overall prevalence of 
RET/PTC diverges between sporadic and radiation- exposed 
PTC but also the prevalence of RET/PTC3 isoform was 
higher than RET/PTC1 in radiation- exposed cases [12, 17].
Recently, another group described that the proportion of 
samples harboring fusion oncogenes in radiation- exposed 
pediatric PTC is markedly higher (85%) from that seen in 
nonradiation- exposed group (33%), while point mutations 
have been mainly found in nonradiation- exposed patients 
than in radiation- exposed PTC patients [18]
Most of the efforts to determine the landscape of pedi-
atric cases have been concentrated in radiation- exposed 
pediatric thyroid cancer, while in the routine most cases 
of thyroid cancer are actually sporadic cases.
The molecular differences between adult and pediatric 
PTC and the fact that fewer genetic events were described 
in pediatric PTC may impact on the utility of molecular 
testing for diagnosis of thyroid nodules in children. In 
fact, the ATA Guidelines for Children with thyroid nodules 
and differentiated thyroid cancer suggested that, although 
in adults molecular testing aids in the management of 
thyroid nodules with indeterminate cytopathology, insuf-
ficient data exist in children to rely on negative genetic 
studies. Therefore, the test cannot be recommended in 
routine clinical on pediatric patients practice until further 
studies are conducted [22].
Table 1. Summary of the clinicopathological features and occurrence of AGK- BRAF fusion oncogene in pediatric thyroid carcinoma.
Case PTC Variant
Age 
(years) Gender
Tumor 
Size  
(cm) Multifocality
Lymph  
node 
Metastasis
Distant 
Metastasis
Extrathyroidal 
extension TNM
Radiation 
Exposure
AGK-
BRAF
1 Classical 7 M 1.4 No Yes No No T1N1M0 No No
21 Follicular 18 F 4.5 No Yes No NA T3N1M0 No No
3 Classical 4 M 1.7 No Yes Yes Yes T4N1M1 No No
4 Classical 13 F 3.2 No No No No T2N0M0 No No
51 Diffuse Sclerosing 17 F 1.5 Yes Yes No No T1N1M0 No No
6 Classical 4 M 0.7 No Yes No Yes T3N1M0 No No
71 Classical 18 F 3.5 Yes Yes No No T2N1M0 No No
8 Follicular 17 F 2.5 No No No No T2N0M0 No No
91 Classical 7 F 6 Yes Yes Yes Yes T4N1M1 No No
101 Follicular 12 M 3 Yes Yes Yes Yes T4N1M1 No No
11 Classical 5 F 3 No Yes Yes Yes T4N1M1 No No
12 Diffuse Sclerosing 13 F 2.5 Yes Yes No No T2N1M0 No No
131 Diffuse Sclerosing 9 M 1.7 Yes Yes Yes Yes T4N1M1 No No
141 Classical 18 F 3.5 No Yes No No T2N1M0 No No
15 Follicular 12 F 1.8 No No No No T1N0M0 No No
16 Classical 12 F NA Yes Yes Yes Yes T4N1M1 No No
17 Follicular 6 F NA NA Yes No NA TxN1M0 No No
181 Follicular 13 M 2 Yes Yes No Yes T4N1M0 No No
19 Encapsulated 10 F 2 No No No No T1N0M0 No No
201 Classical 15 M 4.5 Yes Yes Yes Yes T4N1M1 No Yes
211,2 Follicular 13 F 5 Yes Yes Yes Yes T4N1M1 No Yes
221 Classical 16 F 2 Yes Yes No No T1N1M0 No No
231 Follicular 8 F 2.5 No Yes No No T2N1M0 No No
241 Solid 8 M 0.9 Yes Yes Yes Yes T4N1M1 No No
251 Diffuse Sclerosing 9 F 2.1 No Yes No Yes T4N1M0 No No
26 Classical 7 F 1.6 No No No Yes T3N0M0 No Yes
271 Follicular 6 F 3.5 Yes Yes Yes Yes T4N1M1 No No
28 Follicular 14 F 1.7 No No No No T1N0M0 No No
29 Follicular 18 F 1 No Yes No No T1N1M0 No No
30 Follicular 12 M 2.2 Yes Yes No No T2N1M0 No No
1PTC samples with matched and Lymph node metastasis.
2PTC samples with matched Lymph node metastasis which was positive for AGK- BRAF.
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This study identified the presence of AGK-BRAF fusion 
gene in sporadic pediatric PTC. Although BRAF V600E 
mutation is uncommon in both radiation- exposed and 
sporadic pediatric PTC [12, 15, 24], our findings reveal 
that BRAF fusion might be an alternative mechanism of 
MAPK pathway activation. It has been previously dem-
onstrated that expression of AGK-BRAF in NIH3T3 and 
COS- 7 cells promotes constitutive activation of MAPK 
signaling pathway and induces NIH3T3 cell growth and 
colony formation [18].
The frequency of BRAF fusion in this cohort of sporadic 
cases, one of the largest of literature, was validated using 
different approaches. FISH analysis allowed us to detect 
clonal rearrangements and to ratify tumor heterogeneity. 
Finally, dual- color, break- apart BRAF probe will help us 
to detect the presence of any fusion within the BRAF 
gene in sporadic pediatric cancer.
It has been suggested that biological differences may 
explain the clinical and pathological features differences 
between pediatric and adult patients. It still remains unclear 
Figure 1. Screen for the presence of AGK-BRAF fusion oncogene in sporadic pediatric PTC. Representative results of RT- PCR analysis performed in 
sporadic pediatric PTC (T1- T10). Positive (C+) and negative controls (NTC) were included in each run. Positive cases showed the proper size range 
(113 bp), as showed in C+ and case 20 (T7) (A). Sanger sequencing confirmed the presence of AGK-BRAF fusion oncogene (B). Dual- color, break- 
apart FISH confirmed the breakage of BRAF gene resulting from structural rearrangements BRAF (C). Nuclei exhibiting rearrangement showed the 
presence of one red and green split signals (red arrow), in addition to the fused yellow or red- green signal (white arrow).
A
B
C
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whether AGK-BRAF correlates with clinicopathological 
parameter in PTC such as age, presence of metastases, 
histological subtypes, and advanced clinical stages. In our 
study, AGK-BRAF fusion appears to be related to a more 
aggressive biological behavior, as extrathyroidal extension 
was seen in all patients with AGK-BRAF rearrangement. 
Additionally, multifocality, lymph node, and distant metas-
tasis at diagnosis were observed in two patients out of 
three patients with AGK-BRAF rearrangement. Unfortu-
nately, no clinical information is available for the previ-
ously described AGK-BRAF- positive radiation- exposed PTC 
[18]. Nevertheless, further analysis, ideally multicenter 
studies, is needed to confirm this hypothesis and to better 
elucidate the biological behavior of sporadic pediatric PTC 
with AGK-BRAF fusion gene.
In summary, our findings provide additional insight to 
our current understanding of tumor biology of sporadic 
pediatric PTC. Further efforts should be undertaken to 
define the genomic landscape of sporadic pediatric PTC. 
The knowledge of the molecular events underlying this 
group of patients would be extremely useful to improve 
the accurate diagnosis of thyroid nodules and prevent 
unnecessary thyroid surgeries, allow molecular prognos-
tication and define a therapeutic approach toward sporadic 
PTC patients.
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